Q-Euroseismocardio-T ... Noninvasive measuring of Cardiovascular, Respiratory and Autonomic Nervous System Function
Public support
Provider
Ministry of Education, Youth and Sports
Programme
EUREKA - European co-operation in the sphere of applied and industrial research and development aimed at the support of multinational co-operation among industrial undertakings, research institutes and universities
Call for proposals
EUREKA 6 (SMSM2008OE3)
Main participants
—
Contest type
VS - Public tender
Contract ID
1729/2010-32
Alternative language
Project name in Czech
Q-Euroseismocardio-T... Neinvazivní měření funkcí kardiovaskulárního, respiračního a autonomního nervového systému
Annotation in Czech
Cílem projektu je kvantitativní neinvazivné měření funkcí kardiovaskulárního, respiračního a autonomního nervového systému. Měření a vyhodnocování těchto funkcí bude realizováno konstrukcí nového hardware-software systému - Q-Euroseismokardiograf-T.
Scientific branches
R&D category
VV - Exeperimental development
CEP classification - main branch
EI - Biotechnology and bionics
CEP - secondary branch
FS - Medical facilities, apparatus and equipment
CEP - another secondary branch
ED - Physiology
OECD FORD - equivalent branches <br>(according to the <a href="http://www.vyzkum.cz/storage/att/E6EF7938F0E854BAE520AC119FB22E8D/Prevodnik_oboru_Frascati.pdf">converter</a>)
20601 - Medical engineering<br>20602 - Medical laboratory technology (including laboratory samples analysis; diagnostic technologies) (Biomaterials to be 2.9 [physical characteristics of living material as related to medical implants, devices, sensors])<br>20801 - Environmental biotechnology<br>20802 - Bioremediation, diagnostic biotechnologies (DNA chips and biosensing devices) in environmental management<br>20803 - Environmental biotechnology related ethics<br>20901 - Industrial biotechnology<br>20902 - Bioprocessing technologies (industrial processes relying on biological agents to drive the process) biocatalysis, fermentation<br>20903 - Bioproducts (products that are manufactured using biological material as feedstock) biomaterials, bioplastics, biofuels, bioderived bulk and fine chemicals, bio-derived novel materials<br>30105 - Physiology (including cytology)<br>30401 - Health-related biotechnology<br>30402 - Technologies involving the manipulation of cells, tissues, organs or the whole organism (assisted reproduction)<br>30403 - Technologies involving identifying the functioning of DNA, proteins and enzymes and how they influence the onset of disease and maintenance of well-being (gene-based diagnostics and therapeutic interventions [pharmacogenomics, gene-based therapeutics])<br>30404 - Biomaterials (as related to medical implants, devices, sensors)<br>30405 - Medical biotechnology related ethics<br>40401 - Agricultural biotechnology and food biotechnology<br>40402 - GM technology (crops and livestock), livestock cloning, marker assisted selection, diagnostics (DNA chips and biosensing devices for the early/accurate detection of diseases) biomass feedstock production technologies, biopharming<br>40403 - Agricultural biotechnology related ethics
Completed project evaluation
Provider evaluation
U - Uspěl podle zadání (s publikovanými či patentovanými výsledky atd.)
Project results evaluation
Project terminated by production of 4 apparatus prototypes Q-Euroseismocardio-T with complex technological documentation for series production. Worldwide top product using quantitative seismographic method and the space medicine technologies
Solution timeline
Realization period - beginning
Jan 1, 2008
Realization period - end
Dec 31, 2010
Project status
U - Finished project
Latest support payment
Feb 11, 2010
Data delivery to CEP
Confidentiality
C - Předmět řešení projektu podléhá obchodnímu tajemství (§ 504 Občanského zákoníku), ale název projektu, cíle projektu a u ukončeného nebo zastaveného projektu zhodnocení výsledku řešení projektu (údaje P03, P04, P15, P19, P29, PN8) dodané do CEP, jsou upraveny tak, aby byly zveřejnitelné.
Data delivery code
CEP11-MSM-OE-U/01:1
Data delivery date
Jun 30, 2011
Finance
Total approved costs
5,350 thou. CZK
Public financial support
2,675 thou. CZK
Other public sources
0 thou. CZK
Non public and foreign sources
2,675 thou. CZK